עלון מידע
INDICATIONS [/za_130.html#1]
[/za_130.html#1] [/za_130.html#1]
CONTRA-INDICATIONS [/za_130.html#1]
[/za_130.html#1]
DOSAGE [/za_130.html#1]
[/za_130.html#1]
SIDE-EFFECTS [/za_130.html#1]
[/za_130.html#1] [/za_130.html#1]
PREGNANCY [/za_130.html#1]
[/za_130.html#1]
OVERDOSE [/za_130.html#1]
IDENTIFICATION [/za_130.html#1]
[/za_130.html#1] PATIENT INFORMATION
ADCO-RETIC TABLETS
SCHEDULING STATUS:
S3
PROPRIETARY NAME
(and dosage form):
ADCO-RETIC TABLETS
COMPOSITION:
Each tablet contains 5 mg
AMILORIDE
hydrochloride, and 50 mg
HYDROCHLOROTHIAZIDE
.
PHARMACOLOGICAL CLASSIFICATION:
A 18.1 Diuretics
PHARMACOLOGICAL ACTION:
ADCO-RETIC TABLETS have diuretic and antihypertensive effects, combining the natriuretic action of
hydrochlorothiazide, with the potassium conserving property of amiloride hydrochloride. The mild diuretic action of
amiloride hydrochloride is additive to the natriuretic and diuretic activity of the thiazide.
INDICATIONS:
ADCO-RETIC TABLETS are indicated in the treatment of patients with oedema of cardiac decompensation or associated
with hepatic cirrhosis and corticosteroid therapy. They are also indicated in the treatment of patients with essential
hypertension.
CONTRA-INDICATIONS:
Hyperkalaemia:
ADCO-RETIC TABLETS should not be used in the presence of elevated plasma potassium levels (interpreted as over
5,5 mmol per L).
Antikaliuretic Therapy or Potassium Supplementation:
Other antikaliuretic agents and potassium supplements are contra-indicated in patients receiving
ADCO-RETIC
TABLETS due to the potassium-sparing effect of amiloride hydrochloride (such combination therapy is commonly
associated with rapid increases in plasma potassium levels).
Impaired Renal Function:
Anuria, acute renal failure, severe progressive renal disease and diabetic nephropathy are co
קרא את המסמך השלם
עלון מידע 